References
- Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J. Hypertens.22, 11–19 (2004).
- Mancia G, Ambrosioni E, Agabiti Rosei E, Leonetti G, Trimarco B, Volpe M; ForLife study group. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J. Hypertens.23, 1575–1581 (2005).
- Redon J, Erdine S, Böhm M et al. Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-Wide Survey. J. Hypertens.29, 1633–1640 (2011).
- Rossi GP, Bernini G, Caliumi C et al. A prospective study on the prevalence of primary aldosteronism in 1225 hypertensive patients. J. Am. Coll. Cardiol.48, 2293–2300 (2006).
- Rossi GP, Seccia TM, Pessina AC. Secondary hypertension: the ways to management. Curr. Vasc. Pharmacol.8, 753–768 (2010).
- Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther.23, 1296–1310 (2001).
- Gupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixed-dose combinations of anti-hypertensive agents: a meta-analysis. Hypertension55, 399–407 (2010).
- Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J. Am. Coll. Cardiol.49, 1157–1163 (2007).
- Václavik J, Sedlak R, Plachy M. Addition of Spironolactone in Patients with Resistant Arterial Hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension57, 1069–1075 (2011).
- Rossi GP, Belfiore A, Bernini G et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. Clin. Endocrinol. Metab.93, 2566–2571 (2008).
- Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. Br. Med. J.326, 1419 (2003).
- Bakris GL, Lindholm LH, Black HR et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension56, 824–830 (2010).
- Iglarz M, Binkert C, Morrison K et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonists. J. Pharmacol. Exp. Ther.327, 736–745 (2008).
- Asmar L, Azizi M, Menard J. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension56, 831–838 (2010).
- Wind S, Beuerlein K, Armitage ME et al. Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX½ is reversed by NADPH oxidase inhibition. Hypertension56, 490–497 (2010).
- Tissot AC, Maurer P, Nussberger J et al. Effect of immunization against angiotensin II with CYT006-AngQb on ambulatory pressure: a double-blind, randomised, placebo-controlled Phase IIa study. Lancet371, 821–827 (2008).
- Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet373, 1275–1281 (2009).
- Symplicity HTN2 Investigators. Renal denervation in patients with treatment-resistant hypertension (the Symplicity HTN2 trial): a randomised controlled trial. Lancet376, 1903–1909 (2010).
- Wustmann K, Kucera JP, Scheffers I et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension54, 530–536 (2009).
- Bisognano JD, Kaufman CL, Bach DS, Lovett EG, de Leeuw P, Debut HT; Rheos Feasibility Trial investigators. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J. Am. Col. Cardiol.57, 1787–1798 (2011).